Literature DB >> 18415229

[The estimation of the i.m. morphine-equivalent in cancer pain treatment with different opioids or different routes of administrations. Practical meaning and limitations.].

J Jage1, R K Portenoy, K M Foley.   

Abstract

During the long-term treatment with opioids it is sometimes important to switch the opioid or change the route of administration. The estimation of morphine-equivalents can be helpful in this range because it clarifies the dose in milligramm required for different clinical situations. The basis of this estimation is the equianalgesic potency of opioids. One i.m. morphine-equivalent is the analgesic dose of an opioid (i.m. injected) equal to the analgesic effect of 1 mg morphine (i.m.). The relationships between equianalgesic doses and intramuscular and oral routes of applications are listed in tables. The cross-tolerance between different opioids during long-term treatment is not complete. To avoid an overdose, we suggest a reduction in the calculated opioid dose of 50%. Additional "rescue doses" can be used during the period immediately the change to provied satisfactory pain control. A new opioid dosage should be calculated every 24 hours based on the basaline dose plus the total quantity of "rescue" medication required by the patient. Useful starting point for calculation an effective dose when changing from one opioid or route of administration to another can result in improved pain control that is more responsive to patient need. The limitations are 1. individual differences in the response to opioids, especially during long-term treatment and in the development of analgesic tolerance, 2. individual differences in the response to alternatives routes of administration, and 3. the unknown degree of cross tolerance among opioid drugs. The scientific meaning of the estimation of i.m. morphine-equivalent is discussed.

Entities:  

Year:  1990        PMID: 18415229     DOI: 10.1007/BF02527845

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  23 in total

1.  Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.

Authors:  D Paul; K M Standifer; C E Inturrisi; G W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  1989-11       Impact factor: 4.030

2.  [Not Available].

Authors:  I Jurna
Journal:  Schmerz       Date:  1987-07       Impact factor: 1.107

Review 3.  Multiple morphine and enkephalin receptors and the relief of pain.

Authors:  G W Pasternak
Journal:  JAMA       Date:  1988-03-04       Impact factor: 56.272

4.  Patient-controlled analgesia with extradural morphine or pethidine.

Authors:  S Sjöström; D Hartvig; A Tamsen
Journal:  Br J Anaesth       Date:  1988-03       Impact factor: 9.166

Review 5.  Continuous Sc infusion of narcotics for the treatment of cancer pain: an update.

Authors:  E Bruera; C Brenneis; R N MacDonald
Journal:  Cancer Treat Rep       Date:  1987-10

6.  Clinical evaluation of the new analgesic piritramide.

Authors:  A Saarne
Journal:  Acta Anaesthesiol Scand       Date:  1969       Impact factor: 2.105

7.  Patterns of narcotic drug use in a cancer pain clinic.

Authors:  R M Kanner; K M Foley
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

Review 8.  The treatment of cancer pain.

Authors:  K M Foley
Journal:  N Engl J Med       Date:  1985-07-11       Impact factor: 91.245

9.  Pain scores and ventilatory and circulatory sequelae of epidural morphine in cancer patients with and without prior narcotic therapy.

Authors:  B L Pfeifer; H L Sernaker; U M Ter Horst
Journal:  Anesth Analg       Date:  1988-09       Impact factor: 5.108

10.  Chronic use of opioid analgesics in non-malignant pain: report of 38 cases.

Authors:  Russell K Portenoy; Kathleen M Foley
Journal:  Pain       Date:  1986-05       Impact factor: 6.961

View more
  7 in total

Review 1.  Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.

Authors:  S Grond; L Radbruch; K A Lehmann
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 2.  [Patients with pre-existing chronic pain and/or psychological problems].

Authors:  M Schiltenwolf; R Klinger
Journal:  Orthopade       Date:  2008-10       Impact factor: 1.087

3.  Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding--a pilot study in 20 patients.

Authors:  W Korte; R Morant
Journal:  Support Care Cancer       Date:  1994-03       Impact factor: 3.603

Review 4.  [Drugs for postoperative analgesia: routine and new aspects: Part 2: opioids, ketamine and gabapentinoids].

Authors:  J Jage; R Laufenberg-Feldmann; F Heid
Journal:  Anaesthesist       Date:  2008-05       Impact factor: 1.041

5.  [Experience with intra- and perioperative high-dosage steroids in microneursurgical revision operations on lumbar discs.].

Authors:  F J Prestar; B Jöllenbeck
Journal:  Schmerz       Date:  1995-03       Impact factor: 1.107

6.  [Opioids in "non-malignant" pain-results of long-term treatment in patients with rheumatic disease.].

Authors:  J Sorge; B Steffmann; C Lehmkuhl; I Pichlmayr
Journal:  Schmerz       Date:  1991-06       Impact factor: 1.107

7.  [PRN analgesic drug administration and PCA in children and adults following surgery for funnel chest.].

Authors:  R Sittl; J Tillig; H Huber; N Grießinger; G Braun; A Katalinic
Journal:  Schmerz       Date:  1995-07       Impact factor: 1.107

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.